Dr. Emamekhoo explains the background of the cancer drug shortage
The shortage has been affecting the treatment of patients with genitourinary cancers, including bladder cancer.
In this video, Hamid Emamekhoo, MD, discusses the cause of the ongoing cancer drug shortage that is affecting the treatment of patients across tumor types, including genitourinary malignancies. Emamekhoo is a medical oncologist with a clinical and research focus on genitourinary malignancies at the University of Wisconsin-Madison School of Medicine and Public Health.
Transcript
The current carboplatin and cisplatin shortage is mainly driven by a company that was one of the largest suppliers of these drugs for the United States. After an FDA audit, they noticed some issues with the manufacturing and production process, and that company was shut down. So that caused a significant reduction in the supply for the US market for these generic drugs, cisplatin and carboplatin. The other manufacturers were not able to ramp up the production that fast or that much because these drugs are used to treat multiple types of cancers including some genitourinary malignancies. They’re used for multiple different cancers, such as gynecologic cancers, lung cancer, and head and neck cancers.
Transcript has been edited for clarity.
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
